Syndax Pharmaceuticals Inc

Healthcare · Biotechnology

17.80$ +1.3% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Balance Sheet

Syndax Pharmaceuticals Inc (SNDX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 704 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet SNDX
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	118	109	98	135	124	137	120	105	96	84	99	87	76	64	105	193	179	301	280	263	240	450	422	406	360	497	460	431	399	613	543	477	426	725	641	596	552	530	473	704
Current Assets	117	109	97	134	124	133	119	105	96	83	98	86	75	62	104	192	177	299	279	263	238	448	420	392	358	490	442	409	381	581	454	446	415	603	549	532	530	528	471	675
Cash	13	24	22	23	21	35	28	32	27	34	58	27	31	25	45	54	56	115	64	68	71	222	189	120	71	74	58	97	95	295	115	105	133	154	154	109	117	135	131	336
Cash & Short-Term Investments	116	105	93	130	121	133	113	98	90	81	93	81	72	60	99	187	170	293	271	253	230	447	411	377	351	484	432	406	364	578	435	425	390	583	516	469	454	394	352	548
Receivables	0.2	0.3	0.2	0.4	0.6	0.4	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.3	0.4	0.2	0.4	0.2	14	4.9	4.1	2.1	0.5	4.2	1.2	7.6	11	4.7	14	21	37	43	38	61	70
Inventory	1.2	2.4	3.5	3.1	1.7	-1.4	3.5	4.1	4.5	1.1	3.6	4.0	1.5	1.7	4.3	4.4	6.7	5.3	7.2	8.8	8.1	7.7	2.3	1.9	1.8	-4.3	-9.7	2.2	2.7	2.0	–	–	-4.7	0.4	4.7	18	25	33	35	33
Property, Plant & Equipment	0.3	0.3	0.2	0.3	0.3	0.3	0.4	0.4	0.4	0.4	1.6	1.4	1.1	1.0	0.9	0.7	0.2	0.2	0.2	0.5	0.2	0.3	0.3	1.0	0.0	1.1	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	24	25	25	25	28	33	33	35	32	31	31	32	32	32	52	45	47	48	51	48	40	41	48	44	22	30	24	31	40	59	51	43	59	437	426	439	436	465	431	689
Current Liabilities	9.1	10	11	12	14	16	17	19	17	16	16	17	18	18	19	12	15	19	25	24	29	21	31	31	21	29	24	30	39	58	51	42	59	104	95	113	114	120	86	100
Short-Term Debt	5.7	6.4	–	–	11	12	13	12	12	13	0.5	0.5	0.5	0.5	0.5	0.4	0.4	2.6	5.1	7.4	9.9	0.4	3.9	7.5	0.5	0.4	0.5	1.0	1.0	1.0	1.1	1.0	0.9	13	0.4	0.4	23	0.5	0.5	0.5
Accounts Payable	2.0	2.4	2.7	3.4	2.2	2.2	2.6	5.3	3.2	1.4	4.4	2.3	6.8	6.2	9.0	1.8	3.8	3.5	6.5	3.6	5.1	5.7	8.2	6.4	7.1	4.4	8.1	11	6.0	17	8.8	12	4.9	12	10	17	14	17	11	4.9
Long-Term Debt	–	–	–	–	–	–	–	–	–	–	0.8	–	–	–	20	20	20	18	16	13	11	20	16	13	–	–	–	–	–	–	–	–	–	332	–	–	–	344	344	588
Shareholders' Equity	94	84	73	109	97	104	87	70	64	53	69	55	44	32	54	148	132	252	228	215	199	408	375	362	338	467	436	400	359	554	492	434	366	288	215	157	115	65	42	15
Retained Earnings	-294	-305	-318	-332	-347	-366	-385	-403	-421	-439	-454	-469	-481	-495	-511	-528	-548	-569	-596	-619	-640	-544	-581	-618	-654	-693	-734	-779	-830	-902	-975	-1,043	-1,127	-1,221	-1,306	-1,378	-1,439	-1,507	-1,549	-1,599
Shares Outstanding	18	18	18	19	22	24	24	25	25	27	27	32	32	32	34	41	44	46	51	52	52	53	59	60	61	63	69	70	70	73	85	85	85	86	86	86	87	87	87	89

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings